Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stock Report

Market Cap: US$3.2m

Biodexa Pharmaceuticals Future Growth

Future criteria checks 0/6

Biodexa Pharmaceuticals's revenue is forecast to decline at 85.7% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth21.3%
Revenue growth rate-85.7%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Feb 2024

Recent future growth updates

No updates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Earnings and Revenue Growth Forecasts

NasdaqCM:BDRX - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/AN/A-21-211
12/31/2025N/AN/A-16-161
12/31/2024N/AN/A-11-111
12/31/20230-7-7-7N/A
9/30/20230-8-7-7N/A
6/30/20231-8-7-7N/A
3/31/20231-8-7-7N/A
12/31/20221-8-7-7N/A
9/30/20221-7-7-7N/A
6/30/20221-5-7-6N/A
3/31/20221-5-6-6N/A
12/31/20211-5-6-6N/A
9/30/20211-7-6-6N/A
6/30/20211-8-6-5N/A
3/31/20210-15-8-7N/A
12/31/20200-22-10-9N/A
6/30/20200-22-9-9N/A
3/31/20201-16-8-8N/A
12/31/20191-9-7-6N/A
6/30/20192-9-10-10N/A
3/31/20192-10-12-12N/A
12/31/20182-10-14-13N/A
6/30/20181-11-11-11N/A
3/31/20181-11-13-12N/A
12/31/20171-12-14-13N/A
9/30/2017-3-1N/A-14N/A
6/30/20174-18N/A-15N/A
3/31/20176-19N/A-14N/A
12/31/20161-6N/A-13N/A
9/30/20165-17N/A-14N/A
6/30/20164-13N/A-15N/A
3/31/20163-12N/A-14N/A
12/31/20151-10N/A-12N/A
9/30/20151-10N/A-11N/A
6/30/20150-11N/A-9N/A
3/31/20150-10N/A-7N/A
12/31/20140-9N/A-5N/A
9/30/20140-7N/A-5N/A
6/30/20140-5N/A-5N/A
3/31/20140-4N/A-5N/A
12/31/20130-4N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BDRX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if BDRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if BDRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BDRX is forecast to have no revenue next year.

High Growth Revenue: BDRX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BDRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.